Industry Trends

Combined powers of synbio and biopharma point to bright future for industry.

The recent FDA approval of Biogen’s controversial drug aducanumab is the first drug approved for Alzheimer’s disease in nearly 20 years, and highlights the urgent need for new disease modifying approaches in drug development in this indication.

Biden administration supports a notable increase in funding for public health and research as a lead priority for the coming year.

Developing a diversity mindset may begin at the top levels of the organization, but building diversity into the entire drug development life cycle ensures that it is an ongoing priority and a natural requirement of engaging with external stakeholders.

It's time to apply the same COVID-19 urgency to other devastating diseases, such as Alzheimer’s, write Andrea Pfeifer and William Mobley.

Biopharma companies’ efforts to promote “vaccine equity” and “dose sharing” also aim to limit challenges to international patent protections.

The field of longevity therapeutics — with the goal “of not just adding years to life but adding life to years” — is already disrupting the medical industry, writes Marco Quarta.

The recent flurry of Q1 earnings reports offer a unique opportunity to assess the real-time impacts of COVID-19 on the sector.

Nick Stephens talks to Pharm Exec about how the highs and lows of the executive search business in the last 12 months.

With a new Chinese pharma or biotech company listing on either the HKEX or STAR exchange in China almost every week, it is important consideration US pharma and biotech companies to have a focused China market strategy, writes Enoch Kariuki.

Elizabeth (EJ) Ashbourne, Executive Director of the Partnership for Quality Medical Donations (PQMD), discusses the role of the organization in advancing global health and highlights the benefits offered to members of the pharma industry.

Hannah Schofield and Lavan Thasarathakumar discuss what blockchain is, how it could help improve pharmaceutical supply chains, and the COVID-19 vaccine supply chain in particular, and touches on where we are already seeing blockchain technology being used in this area.

Looking Back at 1994–1996.

To effectively combat the looming threat of antimicrobial resistance, we must prioritize working together to strengthen and more responsibly manage global supply chains.

The drive for “vaccine equity” around the world is bolstering efforts to limit patent protections on innovative medicines and vaccines to combat the global pandemic.

A NASEM report for CDER outlines strategies to modernize pharmaceutical manufacturing to ensure reliable access to high-quality drugs, particularly in response to disruptions caused by the pandemic.

Insights and examples of how collaborative efforts can lead to the development of innovative therapies that target unmet patient needs.

The introduction of alternative payment models and specialty pharmacy benefit management (SPBM) is poised to usher in a new era of affordability for expensive gene therapies.

New data comparing past vs. present experience with telemedicine during the pandemic uncovers insight on how patients, doctors, and payers view the market post-COVID.

at some point, we won’t be seeing wall-to-wall COVID coverage anymore, but stories about the fallout. How can pharmaceutical brands prepare for what’s next?

Looking Back at 1990-1993.

Ahmed Bouzidi explores the opportunities and challenges facing small and mid-size biopharma companies as they strive to bring their latest innovations to market.

It’s important that care for people with pre-existing conditions or at risk from serious diseases does not fall by the wayside.

Henry McNamara, Senior Vice President and General Manager, Oracle Health Sciences, reviews the lessons that the industry has learned over the last year and looks at what lies ahead for pharma in 2021.

Assessing the implications for the pharma industry of the America Rescue Plan Act of 2021, which provides nearly two trillion dollars in funding for various government programs, including many related to public health.

Examining the key biopharma stock numbers and industry trends from a year that challenged the conduct of business and market stability like never before.

Disputes over mRNA-related patents are poised to persist.

Industry makes large investments toward public health issues exposed by pandemic.

Looking back at 1986-1989.

Tracing biopharma’s innovation evolution—and, framed by COVID-19 and the med-tech boon, a look at four notable efforts focused on that one elusive constant: translational value.